WO2012064072A3 - 포스포리파아제 d1억제제를 유효성분으로 포함하는 류마티스 관절염 예방 또는 치료용 조성물 - Google Patents

포스포리파아제 d1억제제를 유효성분으로 포함하는 류마티스 관절염 예방 또는 치료용 조성물 Download PDF

Info

Publication number
WO2012064072A3
WO2012064072A3 PCT/KR2011/008447 KR2011008447W WO2012064072A3 WO 2012064072 A3 WO2012064072 A3 WO 2012064072A3 KR 2011008447 W KR2011008447 W KR 2011008447W WO 2012064072 A3 WO2012064072 A3 WO 2012064072A3
Authority
WO
WIPO (PCT)
Prior art keywords
phospholipase
inhibitor
rheumatoid arthritis
composition
active ingredient
Prior art date
Application number
PCT/KR2011/008447
Other languages
English (en)
French (fr)
Other versions
WO2012064072A2 (ko
Inventor
민도식
유현정
강동우
Original Assignee
부산대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 부산대학교 산학협력단 filed Critical 부산대학교 산학협력단
Publication of WO2012064072A2 publication Critical patent/WO2012064072A2/ko
Publication of WO2012064072A3 publication Critical patent/WO2012064072A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 포스포리파아제 D1 억제제를 유효성분으로 포함하는 류마티스 관절염 예방 또는 치료용 조성물에 관한 것이다. 본 발명의 포스포리파아제 D1 억제제는 관절연골 파괴 억제, 뼈의 파괴 억제 및 염증성 사이토카인 (TNF-a, IL-1β, IL-6 및 IFN-γ, MCP-1 그리고, IL-17)의 생성 억제에 의한 관절부위의 염증을 억제시킴으로써 류마티스 관절염 증상을 현저히 개선시키는 효과를 나타내므로, 이러한 특징을 가진 포스포리파아제 D1 억제제을 유효성분으로 포함하는 본 발명의 조성물은 류마티스성 관절염 예방 또는 치료에 유용하게 사용될 수 있다.
PCT/KR2011/008447 2010-11-09 2011-11-08 포스포리파아제 d1억제제를 유효성분으로 포함하는 류마티스 관절염 예방 또는 치료용 조성물 WO2012064072A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2010-0110791 2010-11-09
KR1020100110791A KR101213070B1 (ko) 2010-11-09 2010-11-09 포스포리파아제 ｄ１억제제를 유효성분으로 포함하는 류마티스 관절염 예방 또는 치료용 조성물

Publications (2)

Publication Number Publication Date
WO2012064072A2 WO2012064072A2 (ko) 2012-05-18
WO2012064072A3 true WO2012064072A3 (ko) 2012-07-19

Family

ID=46051396

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/008447 WO2012064072A2 (ko) 2010-11-09 2011-11-08 포스포리파아제 d1억제제를 유효성분으로 포함하는 류마티스 관절염 예방 또는 치료용 조성물

Country Status (2)

Country Link
KR (1) KR101213070B1 (ko)
WO (1) WO2012064072A2 (ko)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060058365A1 (en) * 2004-08-06 2006-03-16 Kohn Leonard D Compositions and methods for treatment of colitis
US20060093580A1 (en) * 2004-11-04 2006-05-04 Makio Iwashima Tolerogenic vaccine and method

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006133128A2 (en) 2005-06-07 2006-12-14 The Regents Of The University Of California INHIBITION OF EPAC, PHOSPHOLIPASE Cϵ, AND PHOSPHOLIPASE D TO TREAT PAIN

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060058365A1 (en) * 2004-08-06 2006-03-16 Kohn Leonard D Compositions and methods for treatment of colitis
US20060093580A1 (en) * 2004-11-04 2006-05-04 Makio Iwashima Tolerogenic vaccine and method

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JANA A. LEWIS ET AL.: "Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD specificity", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 19, no. 7, 2009, pages 1916 - 1920 *
MI KYUNG PARK ET AL.: "IL-15 promotes osteoclastogenesis via the PLD pathway in rheumatoid arthritis", IMMUNOLOGY LETTERS, vol. 139, no. 1-2, 19 May 2011 (2011-05-19), pages 42 - 51 *
SWAMINATHAN SETHU ET AL.: "Phospholipase D1 Plays a Key Role in TNF-a Signaling", THE JOURNAL OF IMMUNOLOGY, vol. 180, no. 9, 2008, pages 6027 - 6034 *
SWAMINTHAN SETHU ET AL.: "Phospholipase D1 Mediates TNF a-Induced Inflammation in a Murine Model of TNF a-Induced Peritonitis", PLOS ONE, vol. 5, no. 5, May 2010 (2010-05-01), pages E10506 *

Also Published As

Publication number Publication date
KR20120049508A (ko) 2012-05-17
WO2012064072A2 (ko) 2012-05-18
KR101213070B1 (ko) 2012-12-18

Similar Documents

Publication Publication Date Title
ZA200901037B (en) Pyrimidone compounds as GSK-3 inhibitors
MX2020004099A (es) Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo.
WO2012174487A3 (en) Bromodomain inhibitors and uses thereof
WO2008061724A3 (en) Compositions comprising carnosic acid 12-methylether
EP3354640A3 (en) Mif inhibitors and their uses
CA2818187C (en) Bromodomain inhibitors and uses thereof
WO2012156531A3 (en) Lysine demethylase inhibitors such as cyclylcylopropamine derivatives for use in the treatment of inflammatory diseases or conditions
UA109123C2 (uk) Пробіотична композиція для застосування в лікуванні запалення кишечнику
DE602007012133D1 (de) Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
UA92636C2 (en) Tetrahydro-pyrimidoazepines as modulators of trpv1
EA201070328A1 (ru) Соединения триазолопиридина и их применение в качестве ингибиторов ask
IN2012DN00639A (ko)
WO2011025286A3 (ko) 리포테이코익산 유래 당지질 및 이를 포함하는 조성물
EA200901289A1 (ru) Композиции и способы для противовосполительного лечения
WO2014151456A3 (en) Treatment of inflammatory diseases
WO2011041311A3 (en) Compositions and methods for inhibiting inflammation from and rejection of biomaterials and other methods
WO2013177067A3 (en) Herbal composition for treatment of gastrointestinal inflammatory diseases and method to prepare and use thereof
WO2010009809A3 (de) Wirkstoffkombinationen aus anisfruchtextrakt und hyaluronsäure
WO2013000895A9 (en) Dha and epa in the reduction of oxidative stress
WO2014108337A8 (en) Pyrazolyl-based carboxamides i as crac channel inhibitors
WO2014182928A3 (en) Stat6 inhibitors
EA201500737A1 (ru) Пиразолилкарбоксамиды ii в качестве ингибиторов crac каналов
WO2012064072A3 (ko) 포스포리파아제 d1억제제를 유효성분으로 포함하는 류마티스 관절염 예방 또는 치료용 조성물
WO2009124252A3 (en) Methods and compositions for the treatment of rheumatoid arthritis and other inflammatory diseases
WO2011019867A3 (en) Dietary supplements and methods for treating pain and inflammation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11839706

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11839706

Country of ref document: EP

Kind code of ref document: A2